Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA ...

Researchers sought to assess the risk of developing ALL in patients with multiple myeloma treated with lenalidomide.

Am J Health Syst Pharm. 2007;64(17):1799-1807. Despite a similar chemical structure to thalidomide, the toxicity profile of lenalidomide has been shown to be quite different. The major dose ...

The drug, lenalidomide, has been shown to improve remission time in eligible patients and prolong life. Prof Graham Jackson from Freeman Hospital called it a "massive change". The disease goes ...

Daratumumab therapy resulted in superior progression-free survival in frail patients with previously untreated multiple myeloma.

DARZALEX FASPRO ® is a prescription medicine used to treat adult patients with multiple myeloma: · in combination with the medicines bortezomib, lenalidomide, and dexamethasone in newly ...

Daratumumab, hyaluronidase-fihj; 1800mg/30000units; per vial; soln for SC inj; preservative-free. Daratumumab binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing ...

DARZALEX FASPRO ® is a prescription medicine used to treat adult patients with multiple myeloma: · in combination with the medicines bortezomib, lenalidomide, and dexamethasone in newly ...

Opens in a new tab or window SAN DIEGO -- Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and rituximab (Rituxan) resulted in ...

In the treatment of relapsed or refractory follicular lymphoma (R/R FL), the addition of tafasitamab to a standard 2-drug combination of lenalidomide and rituximab (len+R) significantly improves ...